Antiemetic efficacy of the neurokinin‐1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high‐dose cisplatin

BACKGROUND The tendency of chemotherapeutic regimens to cause vomiting is dependent on the individual drugs in the regimen. The authors analyzed data combined from 2 Phase III trials to assess the effect of the neurokinin‐1 (NK1) antagonist aprepitant combined with a 5HT3 antagonist plus a corticost...

Full description

Saved in:
Bibliographic Details
Published in:Cancer 2005-08, Vol.104 (4), p.864-868
Main Authors: Gralla, Richard J., de Wit, Ronald, Herrstedt, Jorn, Carides, Alexandra D., Ianus, Juliana, Guoguang‐Ma, Julie, Evans, Judith K., Horgan, Kevin J.
Format: Article
Language:English
Subjects:
antiemetic
aprepitant
cancer
nausea and vomiting
neurokinin‐1 antagonist
supportive care
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BACKGROUND The tendency of chemotherapeutic regimens to cause vomiting is dependent on the individual drugs in the regimen. The authors analyzed data combined from 2 Phase III trials to assess the effect of the neurokinin‐1 (NK1) antagonist aprepitant combined with a 5HT3 antagonist plus a corticosteroid in a subpopulation receiving > 1 emetogenic chemotherapeutic agent. METHODS In the current study, 1043 cisplatin‐naive patients (42% were women) receiving cisplatin‐based (≥ 70mg/m2) chemotherapy were assigned randomly to a control regimen (ondansetron [O] 32 mg intravenously and dexamethasone [D] 20 mg orally on Day 1; D 8 mg twice daily on Days 2–4) or an aprepitant (A) regimen (A 125 mg orally plus O 32 mg and D 12 mg on Day 1; A 80 mg and D 8 mg once daily on Days 2–3; and D 8 mg on Day 4). Randomization was stratified for use of concomitant chemotherapy and female gender. The primary end point was complete response (no vomiting and no rescue therapy) on Days 1–5 (0–120 hours). Data were analyzed by a modified intent‐to‐treat approach, and logistic regression was used to make treatment comparisons among patients receiving the most frequently coadministered emetogenic concomitant chemotherapy (Hesketh level ≥ 3). RESULTS Among the approximately 13% of patients (n = 81 for A; n = 80 for control) who received additional emetogenic chemotherapy (doxorubicin or cyclophosphamide), the aprepitant regimen provided a 33 percentage‐point improvement in the complete response rate compared with the control regimen. Among the general population, the advantage with aprepitant was 20 percentage points. CONCLUSIONS The current analysis of > 1000 patients from 2 large randomized trials showed that in the subpopulation at increased risk of chemotherapy‐induced nausea and vomiting due to concomitant emetogenic chemotherapy, the addition of aprepitant to standard antiemetics improved protection to an even greater extent than in the general study population. Cancer 2005. © 2005 American Cancer Society. The use of more than one emetogenic drug within a chemotherapeutic regimen is one of the most important risk factors for chemotherapy‐induced nausea and vomiting. Data pooled from 2 large randomized trials showed that in patients taking concomitant emetogenic chemotherapy in addition to cisplatin, the neurokinin‐1 antagonist aprepitant improved protection to an even greater extent than in the general study population.
ISSN:0008-543X
1097-0142
DOI:10.1002/cncr.21222